Cellectis vs Century Therapeutics
CLLS and IPSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLLS and IPSC compare
Century Therapeutics scores higher on the StockData Score (8 against 3 for Cellectis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLLS | IPSC |
|---|---|---|
| Size and price | ||
| Market cap | – | $299M |
| Share price | $1.18 | $1.65 |
| Change, 1 year | −67.7% | 193% |
| Change, 5 years | −86.8% | −92.0% |
| Beta (5Y) | 2.07 | 1.36 |
| Employees | 229 | 78 |
| StockData Score | ||
| Total score | 3 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 1.4× |
| FCF yield | – | −28.5% |
| Growth | ||
| Revenue growth (TTM) | 75.8% | – |
| Revenue growth, 5Y average | 7.4% | – |
| Profitability | ||
| Gross margin | 100% | – |
| Operating margin | −45.3% | – |
| Net margin | −92.7% | – |
| FCF margin | −57.2% | – |
| Return on equity | −97.8% | −51.2% (better) |
| Return on invested capital | −122% (better) | −126% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.6× | – |
| Current ratio | – | 8.74 |
| Altman Z-score | – | −2.08 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.23% |
| Shareholder yield | – | −0.23% |
| Ownership | ||
| Held by institutions | 9.4% | 87.3% |
| Held by insiders | 53.4% | 3.8% |
| Insider net buying, 12 months | – | $10.6K |
| Short interest, % of float | – | 18.4% |
Go deeper
- CLLS stock overview
- CLLS income statement
- CLLS valuation and score
- IPSC stock overview
- IPSC income statement
- IPSC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.